Single-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer

Single-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer

Bibliographic Details
Main Authors:	Xinfeng Wang, Yuan Li, Runsen Jin, Sufei Zheng, Yuejun Luo, Peng Wu, Zhanyu Wang, Yuxin Yao, Nan Sun, Jie He
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-01-01
Series:	Signal Transduction and Targeted Therapy
Online Access:	https://doi.org/10.1038/s41392-022-01226-1

Similar Items

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
by: Runsen Jin, et al.
Published: (2020-08-01)

The TGFβ-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis
by: Sufei Zheng, et al.
Published: (2019-12-01)

PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma
by: Chengming Liu, et al.
Published: (2023-01-01)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
by: Chengming Liu, et al.
Published: (2022-09-01)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
by: Guangjian Yang, et al.
Published: (2022-08-01)

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
by: Yaning Yang, et al.
Published: (2023-11-01)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
by: Chengming Liu, et al.
Published: (2022-05-01)

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
by: Shiqi Mao, et al.
Published: (2023-04-01)

Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)
by: Guangjian Yang, et al.
Published: (2021-12-01)

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
by: Yanhua Tian, et al.
Published: (2022-10-01)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
by: Chengming Liu, et al.
Published: (2022-07-01)

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma
by: Chengming Liu, et al.
Published: (2022-10-01)

Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
by: Yanyan Wu, et al.
Published: (2020-07-01)

Clusterin modulates transdifferentiation of non-small-cell lung cancer
by: Runsen Jin, et al.
Published: (2017-09-01)

Single‐cell transcriptome analysis of tumor‐infiltrating B cells reveals their clinical implications in non‐small cell lung cancer
by: Xia‐Yao Diao, et al.
Published: (2021-01-01)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
by: Hao Chen, et al.
Published: (2023-09-01)

Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer
by: Ying Zhao, et al.
Published: (2022-07-01)

Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer
by: Jian Chen, et al.
Published: (2020-06-01)

Combined detection of aneuploid circulating tumor‐derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non‐small‐cell lung cancer
by: Yuanyuan Lei, et al.
Published: (2020-07-01)

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
by: Xinghao Ai, et al.
Published: (2021-09-01)

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
by: Zhengbo Song, et al.
Published: (2022-02-01)

In-depth analysis of immune cell landscapes reveals differences between lung adenocarcinoma and lung squamous cell carcinoma
by: Xinfeng Wang, et al.
Published: (2024-01-01)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
by: Xinyong Zhang, et al.
Published: (2020-07-01)

Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC
by: Xiao Han, et al.
Published: (2022-09-01)

The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma
by: Liang Zhou, et al.
Published: (2024-08-01)

A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients
by: Yunfang Zhu, et al.
Published: (2024-09-01)

Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report
by: Zi-yan Yang, et al.
Published: (2020-10-01)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
by: Chengming Liu, et al.
Published: (2021-11-01)

Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
by: Jianli Zhao, et al.
Published: (2025-01-01)

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
by: Zhihui Zhang, et al.
Published: (2021-11-01)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023-02-01)

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer
by: Qiyun Shi, et al.
Published: (2023-12-01)

Unveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer
by: Enzhi Yin, et al.
Published: (2024-11-01)

Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity
by: Ruochuan Zang, et al.
Published: (2019-12-01)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
by: Li Wang, et al.
Published: (2022-09-01)

Single-Cell Analysis Reveals Spatial Heterogeneity of Immune Cells in Lung Adenocarcinoma
by: Youyu Wang, et al.
Published: (2021-08-01)

Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes
by: Qi Yang, et al.
Published: (2021-11-01)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
by: Miao Zhang, et al.
Published: (2022-09-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

Case report: Pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma
by: Liquan Zhu, et al.
Published: (2024-07-01)